Disruption of mitochondrial metabolism in systemic lupus erythematosus: multi-omics insights from a patient-derived cohort

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by dysregulated immune responses and metabolic disturbances. Growing evidence implicates mitochondrial dysfunction in the pathogenesis of SLE; however, a comprehensive multi-omics analysis of mitochondrial pathways has been lacking. Here, we originally performed integrative transcriptomic, proteomic, and phosphoproteomic profiling of peripheral blood mononuclear cells (PBMCs) from SLE patients and systematically assessed mitochondrial functional pathways using the MitoCarta3.0 database. Our study revealed widespread dysregulation of mitochondrial processes in SLE. Proteomic analysis revealed significant upregulation of proteins involved in OXPHOS and metabolic pathways, as well as differential expression of proteins associated with mitochondrial transport and ATP synthase complexes. Phosphoproteomic profiling identified marked alterations in PDHA1 phosphorylation (S232/S293/S300), linking disruption of the glycolysis-TCA cycle to SLE pathogenesis. Longitudinal analysis indicated that SDHB expression progressively increased from inactive to active SLE, serving as a marker of disease progression, while NDUFB9 emerged as a key factor sustaining pathological mitochondrial dysfunction. Transcriptomics uncovered key regulatory transcription factors (TFs; e.g., STAT1, RELA, HDAC2) and kinases (e.g., TBK1, IKBKB) associated with SLE pathogenesis, suggesting potential therapeutic targets. Finally, by integrating the molecular alterations in proteins and phosphorylation modifications identified in this study, along with upstream regulatory features of TFs and kinases, we constructed a multi‑level regulatory network depicting mitochondrial dysfunction in SLE. This network provides a systematic framework for understanding the metabolic‑immune interplay in SLE and providing candidate targets that warrant further experimental investigation.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Medicine
Published
2026-09-12
DOI
https://doi.org/10.1007/s10238-026-02298-x
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Disruption of mitochondrial metabolism in systemic lupus erythematosus: multi-omics insights from a patient-derived cohort

Donge Tang, Zhenqiong Liu, Haomiao Wang, Caiwen Wang et al.
Clinical and Experimental Medicine
Systemic Lupus Erythematosus Research
article

Disruption of mitochondrial metabolism in systemic lupus erythematosus: multi-omics insights from a patient-derived cohort

Donge Tang, Zhenqiong Liu, Haomiao Wang, Caiwen Wang, Qinxin Zhang, Yang Ding, Minmin Wu, Li Guo, Wei Zhang
article en

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by dysregulated immune responses and metabolic disturbances. Growing evidence implicates mitochondrial dysfunction in the pathogenesis of SLE; however, a comprehensive multi-omics analysis of mitochondrial pathways has been lacking. Here, we originally performed integrative transcriptomic, proteomic, and phosphoproteomic profiling of peripheral blood mononuclear cells (PBMCs) from SLE patients and systematically assessed mitochondrial functional pathways using the MitoCarta3.0 database. Our study revealed widespread dysregulation of mitochondrial processes in SLE. Proteomic analysis revealed significant upregulation of proteins involved in OXPHOS and metabolic pathways, as well as differential expression of proteins associated with mitochondrial transport and ATP synthase complexes. Phosphoproteomic profiling identified marked alterations in PDHA1 phosphorylation (S232/S293/S300), linking disruption of the glycolysis-TCA cycle to SLE pathogenesis. Longitudinal analysis indicated that SDHB expression progressively increased from inactive to active SLE, serving as a marker of disease progression, while NDUFB9 emerged as a key factor sustaining pathological mitochondrial dysfunction. Transcriptomics uncovered key regulatory transcription factors (TFs; e.g., STAT1, RELA, HDAC2) and kinases (e.g., TBK1, IKBKB) associated with SLE pathogenesis, suggesting potential therapeutic targets. Finally, by integrating the molecular alterations in proteins and phosphorylation modifications identified in this study, along with upstream regulatory features of TFs and kinases, we constructed a multi‑level regulatory network depicting mitochondrial dysfunction in SLE. This network provides a systematic framework for understanding the metabolic‑immune interplay in SLE and providing candidate targets that warrant further experimental investigation.

Clinical and Experimental Medicine
Jiangxi Chest Hospital (CN), Peking University Shenzhen Hospital (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Southern Medical University Shenzhen Hospital (CN), Chongqing Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Openalex Percentile: Top 9%
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.